Ulcerative Colitis

 

Ulcerative Colitis (UC) affects over 1 million people in the Unites States, with these numbers increasing every year. UC is a chronic inflammatory disease affecting the gastrointestinal (GI) tract, resulting in ulcers of the colon and rectum. A large proportion of patients do not respond to current therapies, and there is considerable need to develop improved therapies for UC patients. Vivreon Biosciences is developing an alternative approach to completely and specifically suppress chronic inflammation by targeting the CRAC channel.

 

Our lead molecule, VV2003, is taken orally, potently inhibits inflammatory functions in the colon, and has delivery to the lower bowel without systemic effects. VV2003 is currently undergoing validation and early development studies with support from the National Institute of Allergy and Infectious Diseases.

Therapeutic Program

Indication

Discovery

Development

VV2003: Colon-Targeted

Ulcerative Colitis

Therapeutic Program

Indication

Discovery

Development

VV3000 Series: Neuroprotection

Alzheimer's Disease

Alzheimer's disease

 

Alzheimer's disease (AD) affects over 5.5 million people in the United States, and 1 out of every 10 people over age 65 has AD. AD causes substantial degeneration of healthy brain tissue, resulting in memory loss and disability. Neuroinflammation is an important contributor to AD disease progression, and ongoing neuroinflammation can be visualized in the brains of persons suffering from AD. Brain cells called microglia are the source of inflammation in AD, and mutations in microglia increase the risk of developing AD.

 

Vivreon Biosciences has discovered a potent lead series of candidate neuroprotective therapeutic drugs that enter the brain and block the CRAC channel, which is essential for chronic neurodegenerative microgliosis. This lead drug series is orally bioavailable, readily penetrates into the central nervous system and demonstrates pre-clinical efficacy in an animal model of neuroinflammation. Vivreon is currently performing lead optimization studies with support from the Alzheimer’s Drug Discovery Foundation and the National Institute on Aging.

Therapeutic Program

Indication

Discovery

Development

VV4000 Series: Neuroprotection

Parkinson's Disease

Parkinson's disease

 

Parkinson's disease (PD) is a degenerative brain disease and affects approximately 1 million people in the United States. PD is a progressive disease, beginning as small tremors, and progressing into problems with balance and a slowing of movement. There are currently no drugs available to slow this progression. In PD, brain microglial cells are constantly exposed to α synuclein protein and exist in a state of chronic inflammation.

 

Vivreon Biosciences is developing a therapeutic strategy is to potently and selectively inhibit microglial CRAC activity to suppress microglial inflammation to treat PD. Vivreon’s PD program is currently in the lead optimization stage of drug discovery, and these studies are ongoing with support from the Michael J. Fox Foundation.

Discovery

Development

Therapeutic Program

Indication

Discovery

Development

Therapeutic Program

Indication

Discovery

Development

Vivreon Biosciences

 

Copyright 2017. Vivreon Biosciences. All rights reserved. 

Vivreon Biosciences

Oral Immune Therapeutics